Acetylon announced that Chief also Executive Officer, Walter Ogier, will present an overview of the ongoing company at 1:30 PM today at the 19th Annual Upcoming Leaders in the Biotech Industry Conference, hosted by BioCentury and Thomson Reuters at the Millennium Broadway Hotel & Conference Center in New York City. The American Invents Work provides for prioritized ‘fast track’ study of patent applications that satisfy specific restrictions regarding the quantity and type of examined claims. ‘Given the widespread curiosity in the development of selective histone deacetylase inhibitors, it is important for Acetylon to demonstrate that we have unique, patentable medication candidates within a competitive composition-of-matter field of intellectual residence.’ commented Walter Ogier, CEO of Acetylon.The company is increasing its earnings-per-share assistance range for the full-year from $3.20 – $3.25 to $3.24 – $3.28, excluding specified items, the midpoint which reflects growth of approximately 15 %. In addition, the company is raising its sales forecast to mid-teens growth for the entire year. For the very first time, Abbott offers earnings-per-share guidance for the third-quarter 2008 of $0.76 – $0.78, excluding specified items, the midpoint of which reflects growth of around 15 %.